Molecular docking and ligand specificity in fragment-based inhibitor discovery.
Yu Chen, Brian K Shoichet
Index: Nat. Chem. Biol. 5 , 358-64, (2009)
Full Text: HTML
Abstract
Fragment screens have successfully identified new scaffolds in drug discovery, often with relatively high hit rates (5%) using small screening libraries (1,000-10,000 compounds). This raises two questions: would other noteworthy chemotypes be found were one to screen all commercially available fragments (>300,000), and does the success rate imply low specificity of fragments? We used molecular docking to screen large libraries of fragments against CTX-M beta-lactamase. We identified ten millimolar-range inhibitors from the 69 compounds tested. The docking poses corresponded closely to the crystallographic structures subsequently determined. Notably, these initial low-affinity hits showed little specificity between CTX-M and an unrelated beta-lactamase, AmpC, which is unusual among beta-lactamase inhibitors. This is consistent with the idea that the high hit rates among fragments correlate to a low initial specificity. As the inhibitors were progressed, both specificity and affinity rose together, yielding to our knowledge the first micromolar-range noncovalent inhibitors against a class A beta-lactamase.
Related Compounds
Related Articles:
A metabolite profiling approach to identify biomarkers of flavonoid intake in humans.
2009-12-01
[J. Nucl. Med. 139 , 2309-14, (2009)]
1998-10-02
[J. Biol. Chem. 273(40) , 25974-86, (1998)]
2003-02-01
[Food Chem. Toxicol. 41(2) , 247-58, (2003)]
2002-07-25
[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 775(1) , 115-20, (2002)]
2007-06-01
[Appl. Microbiol. Biotechnol. 75(4) , 899-908, (2007)]